Abstract
Globalizing forces, including increasing interconnectivity in trade, finance, technology, communications, and population mobility, have created impacts and challenges for public health that transcend national boundaries. Neither communicable nor noncommunicable diseases can be contained or addressed solely within individual states. Furthermore, poverty-related diseases (HIV/AIDS, tuberculosis, malaria, etc.), have reached epidemic proportions, and have cross-cutting and complex economic, social, and political determinants and impacts. There is a growing awareness that ‘institutions matter’ in devising responses to complex global health issues (Dodgson et al., 2002; Kickbusch, 1997). One of these, enthusiastically recommended as a model for overcoming existing institutional deficiencies, is the creation of global public-private partnerships in health (GPPPs) (Reinecke et al., 2000). A GPPP is a collaborative relationship formed between at least three parties: (1) a corporation or industry association; (2) intergovernmental organizations; and (3) national authorities (Buse and Walt, 2000). Global public-private partnerships are created to develop new products (that is, drugs and vaccines), improve access to products, assist with global coordination mechanisms, strengthen health care services, provide public advocacy and education and for regulatory and quality assurance purposes (Nishtar, 2004).KeywordsGlobal HealthTotal RevenueDrug PriceCryptococcal MeningitisPatent ProtectionThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call